A phase IIa single-centre, randomised, double-blind, placebo-controlled, two-way cross-over allergen challenge study to evaluate the effect of treatment with once daily AQX-1125 on the late asthmatic response (LAR) to Inhaled Allergen Challenge (IAC) in subjects with mild to moderate atopic asthma.

Trial Profile

A phase IIa single-centre, randomised, double-blind, placebo-controlled, two-way cross-over allergen challenge study to evaluate the effect of treatment with once daily AQX-1125 on the late asthmatic response (LAR) to Inhaled Allergen Challenge (IAC) in subjects with mild to moderate atopic asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2014

At a glance

  • Drugs Rosiptor (Primary)
  • Indications Allergic asthma
  • Focus Therapeutic Use
  • Sponsors Aquinox Pharmaceuticals
  • Most Recent Events

    • 08 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
    • 22 May 2013 Results presented at the 109th International Conference of the American Thoracic Society.
    • 03 Apr 2013 Primary endpoint 'Clinical-response' has been met according to an Aquinox media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top